Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (NASDAQ: TBPH) announced disappointing top-line results from its Phase 2b induction study of izencitinib for ulcerative colitis. The study failed to meet its primary endpoint of change in total Mayo score and the secondary endpoint of clinical remission at week 8 compared to placebo. However, izencitinib was well-tolerated, showing similar adverse event rates to placebo. The company plans to further analyze the study data and upcoming results from ongoing studies, including a Crohn's Phase 2 study expected in early 2022.

Theravance Biopharma reported its Q2 2021 financial results, highlighting a total revenue of $12.9 million, a decrease of $2.1 million year-over-year. Revenue from YUPELRI collaboration with Viatris was $10.9 million, translating to a 35% share of net sales. R&D expenses reduced to $51.1 million, while SG&A expenses rose to $25.9 million. The company closed a public offering raising $115.6 million and anticipates key clinical results for its products in upcoming quarters. Cash position remains strong at $265 million.

Theravance Biopharma (NASDAQ: TBPH) will report its Q2 2021 financial results and provide a business update on August 3, 2021, after market close. A conference call will follow at 5:00 p.m. ET. The company focuses on organ-selective medicines for inflammation and immunology, aiming to enhance therapeutic effectiveness while minimizing side effects. They leverage expertise in developing lung-selective medicines, including FDA-approved YUPELRI for COPD. For more details, visit www.theravance.com.

Theravance Biopharma (NASDAQ: TBPH) has announced the pricing of its public offering of 6.7 million ordinary shares at $15.00 per share, aiming to raise approximately $100.5 million. The offering is set to close on June 29, 2021, subject to customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 1,005,000 additional shares. The offering is led by SVB Leerink and Evercore ISI. Theravance Biopharma has filed the necessary registration with the SEC and will publish a final prospectus supplement shortly.

Theravance Biopharma (NASDAQ: TBPH) announced a proposed public offering of its ordinary shares, which includes a 30-day underwriters' option for an additional 15% of shares. The offering is contingent upon market conditions. Proceeds will primarily fund the development of ampreloxetine for neurogenic orthostatic hypotension and izencitinib for ulcerative colitis and Crohn's disease. Remaining funds will support other clinical initiatives and working capital. The offering is subject to customary closing conditions, and no assurance can be given regarding its completion.

Theravance Biopharma (NASDAQ: TBPH) announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib for hospitalized COVID-19 patients. Despite not meeting the primary endpoint, the trial showed a favorable trend in 28-day all-cause mortality (6 deaths in nezulcitinib group vs. 13 in placebo, HR: 0.42, p=0.08). The trial involved 210 patients and demonstrated good tolerability with lower adverse events compared to the placebo. The company plans to consult with regulatory agencies on further study protocols.

Theravance Biopharma, listed on NASDAQ as TBPH, will participate in the Bank of America 2021 Healthcare Conference on May 13 at 2:45 p.m. ET. CEO Rick E Winningham will present during the event, which can be accessed via a webcast on the company's website. The presentation will focus on the company's mission to develop organ-selective medicines aimed at improving patient outcomes in serious illnesses, particularly in inflammation and immunology.

Theravance Biopharma (TBPH) reported Q1 2021 total revenue of $14.3 million, a decrease of $5.6 million YOY, attributed mainly to collaboration revenue from Viatris. While YUPELRI's market share grew to 19%, overall net sales faced a slight decline. R&D expenses increased to $67.6 million, leading to an operating loss of $83.9 million. The company anticipates full-year R&D expenses between $195 million and $225 million. Notable upcoming clinical milestones include results for nezulcitinib and izencitinib trials expected in Q2 and Q3 2021.

Theravance Biopharma (NASDAQ: TBPH) will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 5:00 p.m. ET. The company focuses on organ-selective medicines and aims to improve patient lives. Its notable product includes YUPELRI® for COPD. This update will provide critical insights into financial performance and business developments crucial for investors.